Clinical trials: Autoimmune Disorder
Rheumatoid Arthritis
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX…
- Trial name
- 986 (NCT01999192)
- Testing
- Tregalizumab
- Where
- 84 sites in United States, Bulgaria and 12 more
- Volunteers
- 321 people
- Sponsor
- Biotest
Osteoarthritis, Rheumatoid Arthritis
Robotic Arm Assisted Total Knee Arthroplasty
The Investigation will be conducted as a single-submission, multi-center study with approval from and in compliance of the Western Institutional Review Board (WIRB).
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis
- Trial name
- NCT02058069
- Testing
- Robotic Arm Assisted Total Knee Arthroplasty
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- MAKO Surgical Corp.
Multiple Sclerosis
Tecfidera Slow-Titration Study
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gastrointestinal (GI) adverse…
- Trial name
- TITRATION (NCT02428231)
- Testing
- dimethyl fumarate
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 62 people
- Sponsor
- Biogen
Inflammation, Rheumatoid Arthritis
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic (the effect of the body on the investigated drug) and signs of clinical efficacy of increasing single…
- Trial name
- NCT00927927
- Testing
- NNC0142-0002
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Sclerosis
HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)
Multiple sclerosis (MS) is an autoimmune disease directed against the Central Nervous System (CNS). Recent studies have indicated that changes in the gut microbiota are associated with disease initiation and progression.
- Trial name
- NCT04574024
- Testing
- NBT-NM108
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Suhayl Dhib-Jalbut, MD
Type 1 Diabetes
A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes
The primary objective of the study is to determine whether the routine use of Continuous Glucose Monitoring (CGM) without Blood Glucose Monitoring (BGM) confirmation is as safe and effective as CGM used as an adjunct to BGM.
- Trial name
- REPLACE-BG (NCT02258373)
- Testing
- CGM+BGM, CGM Only
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Jaeb Center for Health Research
Rheumatoid Arthritis
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking…
- Trial name
- NCT00883896
- Testing
- ILV-094
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 195 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
This study involves Rheumatoid Arthritis patients in regular clinical setting who are already on etanercept treatment and are in remission or in a low disease activity (LDA) state, and is intended to identify parameters that can…
- Trial name
- DOSERA (NCT00858780)
- Testing
- Etanercept
- Where
- 16 sites in Denmark, Finland and 4 more
- Volunteers
- 91 people
- Sponsor
- Pfizer
Congenital Heart Block, Neonatal Lupus
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague…
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Trial name
- PATCH (NCT01379573)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- NYU Langone Health
Pain, Multiple Sclerosis
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.
- Trial name
- NCT01606176
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Jazz Pharmaceuticals
Diabetes Mellitus, Diabetes Mellitus, Type 1
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
The purpose of this clinical investigation is to evaluate the accuracy of the Eversense® continuous Glucose Monitoring System (Eversense® 180 CGM System) measurements when compared with reference standard measurements up to 180…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PROMISE (NCT03808376)
- Testing
- Continuous Glucose Monitoring System
- Where
- 8 sites in United States
- Volunteers
- 208 people
- Sponsor
- Senseonics, Inc.
Multiple Sclerosis, Relapsing-Remitting
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
- Trial name
- NCT01578330
- Testing
- Fingolimod
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01093326
- Testing
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 353 people
- Sponsor
- Actelion
Systemic Lupus Erythematosus, Connective Tissue Disease
On Open-Label Study in Participants With Systemic Lupus Erythematosus
The purpose of this SLE study is to evaluate the long-term safety and efficacy of LY2127399 in eligible SLE participants who have completed the core studies (NCT01196091) (NCT01205438).
- Conditions
- Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
- Trial name
- Illuminate-X (NCT01488708)
- Testing
- LY2127399
- Where
- United States
- Volunteers
- 1,518 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Trial name
- CERTAIN 2 (NCT00843778)
- Testing
- Certolizumab Pegol
- Where
- 25 sites in Austria, France and 3 more
- Volunteers
- 131 people
- Sponsor
- UCB Pharma
Osteoarthritis, Rheumatoid Arthritis
Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement
Prospective, randomized study of Summit Porocoat versus Summit DuoFix HA in total hip arthroplasty
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Avascular Necrosis
- Trial name
- SPD (NCT00306917)
- Testing
- non-coated femoral hip stem, coated femoral hip stem
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- DePuy Orthopaedics
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Rheumatoid Arthritis
A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate
This was a Phase II, randomized, double-blind, multicenter study designed to evaluate the safety and efficacy of rituximab, administered at two different regimens for 2 years, in patients with moderate to severe active rheumatoid…
- Trial name
- RUMBA (NCT00243412)
- Testing
- folate, methotrexate, methylprednisolone
- Volunteers
- 42 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Gait Disorders, Neurologic
Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist.
- Trial name
- NCT04000373
- Testing
- Ekso GT™ exoskeleton
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Cleveland Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.